BRKR vs. BIO, AVTR, WAT, TXG, QTRX, PACB, AXDX, MTD, A, and JNPR
Should you be buying Bruker stock or one of its competitors? The main competitors of Bruker include Bio-Rad Laboratories (BIO), Avantor (AVTR), Waters (WAT), 10x Genomics (TXG), Quanterix (QTRX), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Mettler-Toledo International (MTD), Agilent Technologies (A), and Juniper Networks (JNPR).
Bio-Rad Laboratories (NYSE:BIO) and Bruker (NASDAQ:BRKR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, community ranking, earnings, profitability, valuation, dividends and institutional ownership.
Bruker has a net margin of 14.41% compared to Bruker's net margin of -23.86%. Bio-Rad Laboratories' return on equity of 29.94% beat Bruker's return on equity.
Bruker received 305 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. However, 64.93% of users gave Bio-Rad Laboratories an outperform vote while only 64.91% of users gave Bruker an outperform vote.
Bruker has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.
Bio-Rad Laboratories has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Bruker has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.
In the previous week, Bruker had 10 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 19 mentions for Bruker and 9 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.65 beat Bruker's score of 0.39 indicating that Bruker is being referred to more favorably in the news media.
Bio-Rad Laboratories currently has a consensus target price of $468.00, suggesting a potential upside of 67.56%. Bruker has a consensus target price of $84.86, suggesting a potential upside of 21.07%. Given Bruker's stronger consensus rating and higher possible upside, research analysts plainly believe Bio-Rad Laboratories is more favorable than Bruker.
65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 79.5% of Bruker shares are held by institutional investors. 17.1% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 28.3% of Bruker shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Bruker beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.
Get Bruker News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRKR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
